Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of Tabalumab in Rheumatoid Arthritis
NCT01215942Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2011
- Primary completion
- Feb 2014
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 27
01
Overview
A Phase 3 trial of tabalumab in rheumatoid arthritis (RA), sponsored by Eli Lilly and Company. Started Jun 2011; status: terminated.
02
Drugs
tabalumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01215942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01215942.